Another triple digit gain for the Dow Stocks are enjoying their best back to back gains since the beginning of the year as each of the major equity indices is higher by at least 1%. Advancing stocks are ahead of declining stocks by almost 3:1 on the NYSE and by a bit over 2:1 on the Nasdaq. Up volume is ahead of down volume by 3:1 or more on both. Crude oil prices are nearly unchanged and gold is down over 1%. The Dow is up 154 points, the Nasdaq is up 38 points and the S&P is up 18 points.
News For NOSYMBOL From The Last 14 Days
Check below for free stories on NOSYMBOL the last two weeks.
Futures higher to begin the week Stock futures are higher this morning as the market tries to build on last week’s move. There is little for investors to key in on today as earnings season is winding down and the lone major economic reports scheduled to be released today are the Chicago Fed National Activity index and the Dallas Fed Manufacturing Index. Both are relatively minor in scope, but should give some indication as to how the winter weather affected two different parts of the country
Treasury Market Outlook: Treasuries are little changed Treasury Market Outlook: Treasuries are little changed with the 10-year yield at 2.72%. Bonds were mixed overnight with JGBs and Gilts higher, while German Bunds faded. A stronger JPY weighed on the Nikkei. German Bunds underperformed in Europe after an unexpected rise in the Ifo to 111.3 in February and an upward revision to HICP inflation for January. There is some calm in the Ukraine after the ouster of President Yanukovych. The G20 issued a rather boilerplate statement about boosting growth. Today's U.S. schedule is lean with just the Chicago Fed National Activity index for January. The Treasury will sell $50 B in bills, and the NY Fed will buy $2.50 B to $3.00 B in notes maturing from Nov 2019 - Feb 2021. The market will be looking ahead to the second part of Fed Chair Yellen's Monetary Policy testimony (now slated for Thursday). Supply is heavy with $96 B in coupon offerings and a $13 B 2-year FRN.